{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/ctn-ctx-scheme-management-and-notifications”
},
“@id”: “https://www.clinicalstudies.in/ctn-ctx-scheme-management-and-notifications”,
“headline”: “SOP for CTN and CTX Scheme Management and Notifications”,
“name”: “SOP for CTN and CTX Scheme Management and Notifications”,
“description”: “Comprehensive SOP describing sponsor and investigator obligations for CTN and CTX scheme management, submission and notification procedures, and compliance with TGA GCP requirements.”,
“keywords”: “CTN CTX scheme SOP, TGA clinical trial notifications, CTX submission Australia, CTN sponsor responsibilities, TGA regulatory submissions SOP, Australian clinical trial governance, CTA vs CTX process, clinical trial exemption Australia, trial notification workflow TGA, CTN CTX lifecycle SOP, inspection readiness TGA, sponsor obligations CTN CTX, ethics and TGA coordination SOP, site notification process TGA, CTX documentation requirements, CTN approval workflow, regulatory communication log TGA, quality assurance CTN CTX, submission formatting TGA, site-specific assessment SOP, trial governance SOP Australia, CTN CTX compliance SOP, investigator responsibilities CTN CTX, regulatory reporting TGA, CTN CTX record-keeping”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

CTN and CTX Scheme Management and Notifications SOP

Purpose

This SOP establishes the processes for Clinical Trial Notification (CTN) and Clinical Trial Exemption (CTX) submissions, management, and notifications to the Therapeutic Goods Administration (TGA). It ensures sponsor and investigator responsibilities are defined, submissions are accurate and timely, and clinical trials remain compliant with GCP and Australian regulatory requirements.

Scope

This SOP applies to all clinical trials under the CTN or CTX scheme where the organization is sponsor or delegated sponsor. It covers preparation, submission, acknowledgment, notifications, amendments, site-specific assessments, and ongoing compliance obligations. It applies to Regulatory Affairs, Clinical Research, Pharmacovigilance, Quality Assurance, and Investigator Sites involved in CTN/CTX processes.

Responsibilities

• Regulatory Affairs (RA): Manages CTN/CTX submission preparation, lodgment, and notifications to TGA.
• Principal Investigator (PI): Provides site-specific documents and ensures site compliance with authorized protocol.
• Clinical Project Manager (CPM): Coordinates submissions, timelines, and REB/HREC approvals.
• Pharmacovigilance (PV): Ensures safety reports are submitted to TGA as required under CTN/CTX obligations.
• Quality Assurance (QA): Audits CTN/CTX processes and verifies compliance for inspection readiness.

Accountability

The Head of Clinical Research is accountable for overall compliance with CTN/CTX obligations. Regulatory Affairs is accountable for submission accuracy and timeliness. The PI is accountable for ensuring trial conduct at site level is consistent with approved CTN/CTX conditions.

Procedure

1. Determination of CTN vs CTX Pathway

1. Assess whether the investigational product and trial design require CTN (notification scheme) or CTX (exemption scheme requiring TGA evaluation).
2. Document rationale for pathway selection in Regulatory Justification Memo.

2. Preparation of Submission

1. Compile core documents: protocol, Investigator’s Brochure (IB), informed consent forms (ICFs), CMC data, and ethics approval certificates.
2. For CTN: Prepare notification package for TGA submission.
3. For CTX: Prepare full dossier including preclinical and clinical data for TGA evaluation.

3. Submission Process

1. Submit CTN/CTX via TGA online portal.
2. Record acknowledgment, submission ID, and control number in Regulatory Submission Log.
3. File submission package and acknowledgment in TMF.

4. Amendments

1. Submit substantial amendments to TGA prior to implementation (e.g., protocol changes, safety updates).
2. Update Amendment Log and inform sites and HRECs of approvals.

5. Notifications and Lifecycle Management

1. Notify TGA of trial initiation, site activations, suspensions, and trial closure.
2. Maintain Trial Notification Log capturing submission dates and acknowledgments.

6. Safety Reporting

1. Submit SUSARs, safety updates, and DSURs in compliance with TGA timelines.
2. Maintain Safety Reporting Log and SUSAR Submission Log in TMF.

7. Documentation and Archiving

1. Maintain Regulatory Submission Log, Amendment Log, Safety Reporting Log, and Communication Log in TMF.
2. Archive documents for at least 15 years or per TGA requirements.

Abbreviations

• CTN: Clinical Trial Notification
• CTX: Clinical Trial Exemption
• TGA: Therapeutic Goods Administration
• HREC: Human Research Ethics Committee
• IB: Investigator’s Brochure
• ICF: Informed Consent Form
• CMC: Chemistry, Manufacturing, and Controls
• PV: Pharmacovigilance
• QA: Quality Assurance
• TMF: Trial Master File

Documents

1. Regulatory Submission Log (Annexure-1)
2. Amendment Log (Annexure-2)
3. Trial Notification Log (Annexure-3)

References

• TGA — Clinical Trials Guidance
• ICH E6(R2) Good Clinical Practice
• NHMRC Human Research Ethics Committees

Version: 1.0

Approval

Annexures

Annexure-1: Regulatory Submission Log

Annexure-2: Amendment Log

Annexure-3: Trial Notification Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/hrec-approvals-and-site-specific-assessments”
},
“@id”: “https://www.clinicalstudies.in/hrec-approvals-and-site-specific-assessments”,
“headline”: “SOP for HREC Approvals and Site-Specific Assessments”,
“name”: “SOP for HREC Approvals and Site-Specific Assessments”,
“description”: “Comprehensive SOP describing workflows for obtaining Human Research Ethics Committee (HREC) approvals and Site-Specific Assessments (SSA), ensuring clinical trial start-up compliance with TGA and GCP.”,
“keywords”: “HREC approval SOP, site-specific assessment SSA, ethics submission Australia, HREC site governance SOP, clinical trial ethics workflow, TGA trial governance SOP, SSA application process, ethics documentation SOP, multi-site trial ethics approvals, HREC correspondence log, site ethics responsibilities, investigator obligations ethics, sponsor responsibilities ethics Australia, inspection readiness ethics SOP, HREC-TGA coordination, SSA document review SOP, ethics committee approval timelines, SOP for ethics submissions Australia, trial start-up SOP ethics, REB vs HREC SOP, ethics reporting SOP Australia, SSA approval governance, site initiation ethics SOP, SOP for trial governance Australia, HREC compliance SOP”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

HREC Approvals and Site-Specific Assessments SOP

Purpose

This SOP outlines the standardized processes for obtaining Human Research Ethics Committee (HREC) approvals and conducting Site-Specific Assessments (SSA) before trial initiation. It ensures compliance with TGA regulations, GCP principles, and institutional governance requirements for ethical trial conduct in Australia.

Scope

This SOP applies to all clinical trials conducted under the CTN/CTX schemes in Australia. It covers sponsor, CRO, and investigator responsibilities for submitting documents to HRECs, managing SSA applications, coordinating site governance approvals, and maintaining documentation in TMF and ISF. It also includes communication pathways with institutions, sponsors, and TGA.

Responsibilities

• Principal Investigator (PI): Submits site documents for SSA, responds to HREC queries, and ensures site compliance with approval conditions.
• Clinical Research Coordinator (CRC): Assists in preparing submissions, maintains SSA documentation, and ensures timely renewals.
• Regulatory Affairs (RA): Oversees multi-site HREC submissions and ensures alignment with CTN/CTX submissions to TGA.
• Clinical Project Manager (CPM): Tracks timelines, manages site readiness, and ensures approvals are in place before trial start.
• Quality Assurance (QA): Audits HREC and SSA submissions to ensure compliance and inspection readiness.

Accountability

The Sponsor’s Head of Clinical Research holds accountability for ensuring that all clinical trial sites have valid HREC approvals and completed SSAs prior to activation. The PI is accountable for maintaining ongoing compliance at the site level.

Procedure

1. HREC Submission

1. Compile required documents: protocol, IB, ICFs, investigator CVs, recruitment materials, and insurance certificates.
2. Submit initial package to HREC for review and approval.
3. Record submission date, reference number, and approval status in HREC Submission Log.

2. Site-Specific Assessment (SSA)

1. Submit SSA application with local governance documents including indemnity agreements, budget, and site capabilities.
2. Ensure institutional approvals are obtained prior to participant enrollment.
3. Maintain SSA status tracker with submission, approval, and expiry dates.

3. Amendments

1. Submit substantial amendments (protocol changes, revised ICFs) to HREC and SSA offices prior to implementation.
2. Document approval acknowledgments in TMF and ISF.

4. Renewals and Continuing Review

1. Prepare annual reports for HREC and SSA renewal at least 30 days before expiry.
2. Track renewal timelines in HREC/SSA Renewal Log.

5. Communication and Documentation

1. Maintain logs of HREC and SSA correspondence.
2. File all approvals, acknowledgments, and queries in TMF and ISF.
3. Ensure availability for regulatory and institutional inspections.

Abbreviations

• HREC: Human Research Ethics Committee
• SSA: Site-Specific Assessment
• CTN: Clinical Trial Notification
• CTX: Clinical Trial Exemption
• PI: Principal Investigator
• IB: Investigator’s Brochure
• ICF: Informed Consent Form
• CRC: Clinical Research Coordinator
• TMF: Trial Master File
• ISF: Investigator Site File
• QA: Quality Assurance

Documents

1. HREC Submission Log (Annexure-1)
2. SSA Status Tracker (Annexure-2)
3. HREC/SSA Correspondence Log (Annexure-3)

References

• TGA — Clinical Trials Guidance
• NHMRC Human Research Ethics Committees
• ICH E6(R2) Good Clinical Practice

Version: 1.0

Approval

Annexures

Annexure-1: HREC Submission Log

Annexure-2: SSA Status Tracker

Annexure-3: HREC/SSA Correspondence Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/susar-reporting-to-tga-and-privacy-requirements”
},
“@id”: “https://www.clinicalstudies.in/susar-reporting-to-tga-and-privacy-requirements”,
“headline”: “SOP for SUSAR Reporting to TGA and Privacy Requirements”,
“name”: “SOP for SUSAR Reporting to TGA and Privacy Requirements”,
“description”: “Comprehensive SOP outlining the process for reporting SUSARs and SAEs to the TGA, including timelines, documentation, and adherence to Australian privacy regulations.”,
“keywords”: “SUSAR reporting SOP TGA, safety reporting Australia, adverse event reporting SOP, SUSAR timelines TGA, SAE reporting compliance, clinical safety submissions TGA, pharmacovigilance SOP Australia, expedited safety reporting TGA, SUSAR workflow SOP, investigator responsibilities SUSAR, sponsor obligations SUSAR, safety narratives TGA SOP, ICSR submissions Australia, inspection readiness SUSAR TGA, clinical trial SUSAR governance, privacy requirements safety reporting, SAE SUSAR compliance SOP, SUSAR case log TGA, regulatory safety SOP Australia, data protection SUSAR reports, SUSAR reporting to ethics committees, SAE regulatory submissions TGA, sponsor safety monitoring SOP, SUSAR case management Australia, pharmacovigilance QA SOP”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

SUSAR Reporting to TGA and Privacy Requirements SOP

Purpose

The purpose of this SOP is to define the requirements for reporting Suspected Unexpected Serious Adverse Reactions (SUSARs) and Serious Adverse Events (SAEs) to the Therapeutic Goods Administration (TGA). It ensures compliance with GCP, CTN/CTX obligations, and Australian privacy regulations while protecting subject safety and maintaining sponsor responsibilities for pharmacovigilance.

Scope

This SOP applies to all clinical trials conducted under CTN/CTX schemes requiring safety reporting to TGA. It includes expedited reporting of SUSARs, SAE documentation, case narrative preparation, ICSR submissions, and privacy protection requirements in line with the Australian Privacy Act and local institutional policies.

Responsibilities

• Principal Investigator (PI): Identifies and reports SAEs to sponsor within 24 hours, provides causality assessment, and maintains documentation.
• Clinical Research Coordinator (CRC): Completes SAE forms, verifies medical records, and assists in subject re-consent where applicable.
• Pharmacovigilance (PV) Team: Performs medical review, prepares SUSAR narratives, and ensures submissions to TGA within mandated timelines.
• Regulatory Affairs (RA): Confirms acknowledgments from TGA and ensures SUSAR submissions are filed in TMF.
• Quality Assurance (QA): Reviews safety workflows, audits case files, and ensures privacy compliance.

Accountability

The Sponsor’s Qualified Safety Officer is accountable for ensuring accurate and timely SUSAR and SAE reporting to TGA. The Head of Clinical Research is accountable for monitoring compliance across trials.

Procedure

1. SAE and SUSAR Identification

1. Investigators record SAEs immediately upon awareness using SAE Report Form.
2. Determine seriousness, causality, and expectedness against Investigator’s Brochure (IB) or Reference Safety Information (RSI).
3. Forward initial SAE reports to sponsor PV team within 24 hours.

2. Expedited SUSAR Reporting to TGA

1. Fatal or life-threatening SUSARs: report within 7 calendar days, followed by complete data within 8 additional days.
2. All other SUSARs: report within 15 calendar days.
3. Reports must be submitted in E2B(R3) electronic format via TGA eBusiness portal.

3. Privacy and Data Protection

1. Ensure SAE/SUSAR forms do not contain direct identifiers (e.g., names, addresses) before submission.
2. Subject IDs and trial numbers must be used instead of personal identifiers.
3. Comply with the Australian Privacy Act 1988 and institutional data protection policies.

4. Narrative Preparation

1. PV team prepares comprehensive narratives including demographics, medical history, event description, treatment, and outcome.
2. Narratives must be translated into English if required and archived in TMF.

5. DSUR and Periodic Reports

1. Prepare annual Development Safety Update Reports (DSURs) for cumulative safety data and submit to TGA within 60 days of data lock point.
2. Provide summaries to HRECs as per institutional requirements.

6. Documentation and Archiving

1. Maintain SAE Case Files, SUSAR Logs, and Privacy Compliance Logs.
2. Archive safety records for 15 years or per TGA guidance.

Abbreviations

• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR: Development Safety Update Report
• ICSR: Individual Case Safety Report
• PI: Principal Investigator
• PV: Pharmacovigilance
• RA: Regulatory Affairs
• QA: Quality Assurance
• IB: Investigator’s Brochure
• RSI: Reference Safety Information
• TMF: Trial Master File
• HREC: Human Research Ethics Committee

Documents

1. SAE Reporting Form (Annexure-1)
2. SUSAR Submission Log (Annexure-2)
3. Privacy Compliance Log (Annexure-3)

References

• TGA — Safety Reporting Requirements
• ICH E6(R2) Good Clinical Practice
• ICH E2A: Clinical Safety Data Management
• ICH E2F: Development Safety Update Report
• Australian Privacy Act 1988

Version: 1.0

Approval

Annexures

Annexure-1: SAE Reporting Form

Annexure-2: SUSAR Submission Log

Annexure-3: Privacy Compliance Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/insurance-and-indemnity-requirements”
},
“@id”: “https://www.clinicalstudies.in/insurance-and-indemnity-requirements”,
“headline”: “SOP for Insurance and Indemnity Requirements”,
“name”: “SOP for Insurance and Indemnity Requirements”,
“description”: “Comprehensive SOP defining insurance and indemnity requirements for clinical trials under TGA oversight, including sponsor responsibilities, site obligations, and compliance with GCP.”,
“keywords”: “insurance requirements clinical trials, indemnity SOP Australia, CTN CTX insurance compliance, trial indemnity requirements TGA, investigator indemnity SOP, site insurance SOP, sponsor insurance obligations Australia, indemnity agreement SOP, TGA trial governance, site indemnity documentation, ethics approval insurance requirements, clinical trial insurance checklist, sponsor indemnification responsibilities, Australian trial insurance SOP, SSA insurance requirements, trial governance indemnity, site indemnity verification SOP, indemnity certificate SOP Australia, insurance policy documentation SOP, subject insurance requirements, insurance compliance Australia, indemnity in CTN CTX schemes, ethics indemnity approval, SOP for indemnity records, trial sponsor insurance QA SOP”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Insurance and Indemnity Requirements SOP

Purpose

The purpose of this SOP is to establish requirements for insurance and indemnity in clinical trials conducted under the CTN/CTX schemes in Australia. It ensures sponsor, site, and investigator compliance with TGA, Human Research Ethics Committee (HREC), and institutional governance requirements to safeguard participant rights and provide indemnity coverage for clinical trial-related injuries.

Scope

This SOP applies to all clinical trials sponsored or managed by the organization in Australia requiring insurance and indemnity arrangements. It covers sponsor obligations for trial insurance, indemnity agreements with investigators and sites, documentation requirements, and institutional governance compliance. It also applies to multi-site trials requiring SSA documentation of insurance arrangements.

Responsibilities

• Sponsor: Secures insurance policy covering trial participants for injury or harm related to investigational products and trial procedures.
• Principal Investigator (PI): Ensures site staff are informed of indemnity arrangements and provides indemnity certificates to site governance offices.
• Regulatory Affairs (RA): Confirms insurance documents are filed with CTN/CTX submissions and SSA applications.
• Clinical Project Manager (CPM): Coordinates insurance certificates for each site and maintains tracking logs.
• Quality Assurance (QA): Audits insurance and indemnity records for inspection readiness.

Accountability

The Sponsor is accountable for ensuring valid insurance and indemnity coverage throughout the trial duration. The Head of Clinical Research is accountable for maintaining oversight of insurance arrangements across all trials.

Procedure

1. Insurance Policy Requirements

1. Obtain trial insurance policy covering clinical trial liability, participant compensation, and investigator indemnity.
2. Ensure policy meets Australian law and HREC requirements.
3. Maintain policy validity throughout the study with no lapses in coverage.

2. Indemnity Agreements

1. Prepare indemnity agreements for investigators and institutions using Medicines Australia Standard Indemnity templates.
2. Ensure indemnity agreements are executed before trial initiation at each site.
3. File signed agreements in TMF and ISF.

3. Documentation for Ethics and Governance

1. Submit copies of insurance policies and indemnity agreements with HREC and SSA applications.
2. Record acknowledgments and approvals in Insurance Documentation Log.

4. Monitoring and Renewals

1. Monitor policy expiry dates and renew coverage before lapse.
2. Update insurance certificates for protocol amendments or trial extensions.

5. Archiving

1. Archive insurance and indemnity documents for a minimum of 15 years or as per institutional requirements.

Abbreviations

• CTN: Clinical Trial Notification
• CTX: Clinical Trial Exemption
• TGA: Therapeutic Goods Administration
• HREC: Human Research Ethics Committee
• SSA: Site-Specific Assessment
• PI: Principal Investigator
• CPM: Clinical Project Manager
• RA: Regulatory Affairs
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. Insurance Documentation Log (Annexure-1)
2. Indemnity Agreement Template (Annexure-2)
3. Insurance Certificate Tracker (Annexure-3)

References

• TGA — Clinical Trials Guidance
• Medicines Australia Standard Indemnity
• ICH E6(R2) Good Clinical Practice

Version: 1.0

Approval

Annexures

Annexure-1: Insurance Documentation Log

Annexure-2: Indemnity Agreement Template

Annexure-3: Insurance Certificate Tracker

Revision History

For more SOPs visit: Pharma SOP.